Ivan Griffin

BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom.

Nesta Investment Management LLP. (NESTA Investments) subsidiary of Nesta formerly NESTA, is a venture capital firm founded in 1998. The firm is headquartered in London city United Kingdom.

Cerogenix Ltd. provides pharmaceutical research and development services. The company focuses on developing therapeutics for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. Cerogenix was founded in September, 2005 by Adrian Pini and is located in London, UK

Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million.

Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality.